Physician profile
Lance Long
NPI 1265424303
$9,674.55
in general payments reported to CMS, 2019-2025
22 companies · $1,821 in 2025
The $1,821 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $646 · 2021: $997 · 2022: $985 · 2023: $1,267 · 2024: $2,911 · 2025: $1,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,998.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,802.33 | 2019-2025 | Tryptyr, Total30, Rocklatan |
| Visioneering Technologies, INC. | $1,752.85 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $1,583.58 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $730.63 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $663.06 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $591.80 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $376.40 | 2019-2025 | Acuvue |
| Abbvie INC. | $364.06 | 2022-2025 | |
| Oyster Point Pharma, INC. | $342.73 | 2023-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $223.60 | 2019-2021 | |
| Allergan, INC. | $215.00 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $200.50 | 2021-2022 | |
| Shire North American Group INC | $154.28 | 2019 | |
| Aerie Pharmaceuticals, INC. | $147.17 | 2019-2020 | |
| Genentech USA, INC. | $131.45 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $130.18 | 2024-2025 | Vevye |
| Coopervision INC. | $115.92 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $83.51 | 2023 | Syfovre |
| Derma Sciences, INC. | $21.82 | 2019 | |
| Lkc Technologies, INC. | $15.15 | 2025 | |
| Spark Therapeutics, INC. | $14.88 | 2022 | |
| Synergeyes, INC. | $13.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.